• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Pplpharma Share Price

    Piramal Pharma Share PricePiramal Pharma

    Mid Cap 40.7k Result
    ₹126.2
    -0.4 (-0.32%)
    As on 03 December, 2023 | 06:11 BSE: 543635 NSE: PPLPHARMAISIN: INE0DK501011

    Piramal Pharma Performance

    Day Range

    • Low 124.20
    • High 128.20
    ₹ 126.2

    52 Week Range

    • Low 61.62
    • High 142.38
    ₹ 126.2
    • Open Price126.45
    • Previous Close126.60
    • Volume7239820

    Start SIP in Piramal Pharma

    Start SIP

    Piramal Pharma Share Price

    • Over 1 Month 18.39%
    • Over 3 Month 21.4%
    • Over 6 Month 59.54%
    • Over 1 Year -6.32%

    Piramal Pharma Key Statistics

    P/E Ratio -124.9
    PEG Ratio 0.8
    Market Cap Cr 16,697
    Price to Book Ratio 2.5
    EPS 0.5
    Dividend 0
    Relative Strength Index 71.54
    Money Flow Index 83.34
    MACD Signal 5.29
    Average True Range 4.68

    Piramal Pharma Investment Rating

    • Master Rating:

    • Piramal Pharma has an operating revenue of Rs. 7,539.78 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of -2% needs improvement, ROE of -2% is poor and needs improvement. The company has a reasonable debt to equity of 50%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 18% and 39% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 15% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 73 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Piramal Pharma Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 9948461,0558138297461,127
    Operating Expenses Qtr Cr 908830965786782813945
    Operating Profit Qtr Cr 8617902747-66182
    Depreciation Qtr Cr 51505347474551
    Interest Qtr Cr 28343433292020
    Tax Qtr Cr 19-824335-735
    Net Profit Qtr Cr 77-3342-247-17151
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 3,7843,319
    Operating Expenses Annual Cr 3,3462,698
    Operating Profit Annual in Cr 98397
    Depreciation Cr 192131
    Interest Annual Cr 11654
    Tax Annual Cr 5481
    Net Profit Annual Cr 70343
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 72255
    Cash from Investing Activity Annual Cr -435-1,223
    Cash from Financing Annual Activity Cr 290906
    Net Cash Flow Annual Cr -73-62
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 5,2625,067
    Fixed Assets Annual Cr 3,0181,814
    Total Non Current Assets Annual Cr 5,6945,250
    Total Current Assets Annual Cr 2,3491,958
    Total Assets Annual Cr 8,0427,208
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 4443
    ROE Annual % 17
    ROCE Annual % 49
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1320
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 1,9111,7492,1641,7161,7201,4822,131
    Operating Expenses Qtr Cr 1,6461,6171,8121,6291,5471,4651,733
    Operating Profit Qtr Cr 2661323518717317398
    Depreciation Qtr Cr 185174184164166162165
    Interest Qtr Cr 11011910495836257
    Tax Qtr Cr 35-9451711-669
    Net Profit Qtr Cr 5-9950-90-37-109204
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 7,3076,835
    Operating Expenses Annual Cr 6,4535,609
    Operating Profit Annual in Cr 628950
    Depreciation Cr 677586
    Interest Annual Cr 344198
    Tax Annual Cr 66109
    Net Profit Annual Cr -186376
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 484766
    Cash from Investing Activity Annual Cr -1,339-1,812
    Cash from Financing Annual Activity Cr 818794
    Net Cash Flow Annual Cr -37-251
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 6,7746,697
    Fixed Assets Annual Cr 7,7807,021
    Total Non Current Assets Annual Cr 9,6878,730
    Total Current Assets Annual Cr 4,8354,067
    Total Assets Annual Cr 14,52312,797
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 5756
    ROE Annual % -36
    ROCE Annual % 27
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1219
    Invest in Piramal Pharma

    Piramal Pharma Technicals

    EMA & SMA

    Current Price
    ₹126.2
    -0.4 (-0.32%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹118.15
    • 50 Day
    • ₹110.29
    • 100 Day
    • ₹104.48
    • 200 Day
    • ₹102.99
    • 20 Day
    • ₹118.75
    • 50 Day
    • ₹106.52
    • 100 Day
    • ₹103.42
    • 200 Day
    • ₹90.40

    Piramal Pharma Resistance and Support

    PIVOT
    ₹126.2
    Resistance
    First Resistance 128.20
    Second Resistance 130.20
    Third Resistance 132.20
    RSI 71.54
    MFI 83.34
    MACD Single Line 5.29
    MACD 5.54
    Support
    First Resistance 124.20
    Second Resistance 122.20
    Third Resistance 120.20

    Piramal Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 7,631,577 409,892,001 53.71
    Week 7,197,392 323,018,964 44.88
    1 Month 11,225,621 455,198,932 40.55
    6 Month 8,567,232 391,608,195 45.71

    Piramal Pharma Result Highlights

    Piramal Pharma Synopsis

    NSE-Medical-Diversified

    Piramal Pharma is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 3443.22 Cr. and Equity Capital is Rs. 1193.32 Cr. for the Year ended 31/03/2023. Piramal Pharma Ltd. is a Public Limited Listed company incorporated on 04/03/2020 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is U24297MH2020PLC338592 and registration number is 338592.
    Market Cap 16,697
    Sales 3,709
    Shares in Float 86.00
    No of funds 182
    Yield
    Book Value 2.92
    U/D Vol ratio 2.6
    LTDebt / Equity 11
    Alpha -0.03
    Beta 1.69

    Piramal Pharma

    Owner NameSep-23Aug-23Jun-23Mar-23
    Promoters 35.02%35.02%34.79%34.79%
    Mutual Funds 3.8%3.62%0.91%0.53%
    Insurance Companies 3.8%3.82%4.21%4.18%
    Foreign Portfolio Investors 14.33%14.18%15.01%19.28%
    Financial Institutions/ Banks
    Individual Investors 16.95%16.81%16.77%13.94%
    Others 26.1%26.55%28.31%27.28%

    Piramal Pharma Management

    Name Designation
    Mrs. Nandini Piramal Chairperson
    Mr. Peter DeYoung Executive Director
    Mr. Vivek Valsaraj Executive Director & CFO
    Mr. Neeraj Bharadwaj Non Executive Director
    Mr. Nathalie Leitch Non Executive Director
    Mr. S Ramadorai Independent Director
    Mr. Jairaj Purandare Independent Director
    Mr. Peter Stevenson Independent Director
    Mr. Sridhar Gorthi Independent Director
    Ms. Vibha Paul Rishi Independent Director

    Piramal Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Piramal Pharma Corporate Action

    Date Purpose Remarks
    2023-10-27 Quarterly Results
    2023-08-03 Quarterly Results
    2023-05-24 Audited Results
    2023-02-08 Quarterly Results & Rights issue
    2022-11-08 Quarterly Results

    Piramal Pharma MF Shareholding

    Name Amount(cr)
    ICICI Prudential Value Discovery Fund Growth 32,494
    ICICI Prudential Equity & Debt Fund Growth 26,183
    Quant Small Cap Fund Growth 9,521
    ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth 3,271
    Tata Mid Cap Growth Fund Regular Growth 2,521

    Piramal Pharma FAQs

    What is Share Price of Piramal Pharma ?

    Piramal Pharma share price is ₹126 As on 03 December, 2023 | 05:57

    What is the Market Cap of Piramal Pharma ?

    The Market Cap of Piramal Pharma is ₹16696.6 Cr As on 03 December, 2023 | 05:57

    What is the P/E ratio of Piramal Pharma ?

    The P/E ratio of Piramal Pharma is -124.9 As on 03 December, 2023 | 05:57

    What is the PB ratio of Piramal Pharma ?

    The PB ratio of Piramal Pharma is 2.5 As on 03 December, 2023 | 05:57

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.